Brain Tumor Center Update

Current Clinical Trials for Adults with Brain Tumor
UCSF Cancer Center  •  UCSF Brain Tumor Program
Department of Neurological Surgery & Brain Tumor Research Center

Questions about patients’ participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for adults being performed through the North American Brain Tumor Consortium (NABTC), visit: <http://www.nabtc.org/>

**Newly Diagnosed Glioblastoma Multiforme**

- Phase II Study of PolyICLC plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme (NABTC 01-05)
- Phase I Study of R115777 plus Radiation for Newly Diagnosed Patients with Glioblastoma Multiforme (NABTC 02-02)

**Newly Diagnosed Anaplastic Astrocytoma**

- A Phase I/II Randomized Study of Radiation Therapy and Temozolomide vs Radiation Therapy and BCNU vs Radiation Therapy and Temozolomide and BCNU for Anaplastic Astrocytoma (RTOG 9813)

**Newly Diagnosed Low-Grade Glioma**

- A Phase I Study of Temozolomide (SCH 52365) in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma

**Recurrent Tumor**

- Phase I/II Trial of CCI-779 in Patients with Malignant Glioma (NABTC 01-01)
- A Phase I Study of OSI-774 and Temozolomide for the Treatment of Gliomas
- ZD 1893 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study with a Phase I Component for Patients Receiving EIAEDs (NABTC 00-01)
- A Phase I/II Trial of OSI-774 in Patients with Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy (NABTC 01-03)
- A Phase II Trial of Poly ICLC in Patients with Recurrent Anaplastic Glioma (NABTC 01-06)
- A Multicenter Phase I Study of TP-38 in Those Patients With Glioblastoma Multiforme [that has] Recurred or Progressed After Previous Resection and Radiation Therapy and [Is] Scheduled for Gross Total Resection
- Phase II, Multicenter Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients with First Relapse of Grade IV Glioma (Glioblastoma Multiforme) (OSI2691G)
- Phase II Trial of ST1571 in Patients with Recurrent Meningioma (NABTC 01-08)

**Non-Chemotherapy Protocols**

- Assessment of Needs for [a] Complementary Medicine Program for Patients with Brain Tumors
- Study of Distant Healing as an Adjunctive Intervention in Glioblastoma
- San Francisco Bay Area Adult Glioma Prognosis Study
- A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas
- A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
Questions about patients' participation in the following clinical trials can be directed to Jane Rabbitt or Margaretta Page by calling 415-353-2966, or by email to Mary Malec at malecm@neurosurg.ucsf.edu.

For further details about clinical trials for children being performed through the Pediatric Brain Tumor Consortium (PBTC), visit: <http://www.pbtc.org/>

Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors (PBTC 001)

This is a risk adapted, multi-modality trial for patients under the age of 3 years newly diagnosed with medulloblastoma/PNET, metastatic ependymoma, or other primary intracranial embryonal tumors. For further details: <http://www.pbtc.org/public/PBTC001_HP_abstract.htm>

Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors (PBTC 003)

This is a phase I trial for patients 21 years of age or less with recurrent or progressive brain tumors. For further details: <http://www.pbtc.org/public/PBTC003_HP_abstract.htm>

Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors (PBTC005)

This is a phase I trial for patients with recurrent or refractory pediatric brain tumors. For further details: <http://www.pbtc.org/public/PBTC005_HP_abstract.htm>

Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Glioma and Recurrent Intracranial Malignant Glioma (PBTC 006)

This is a phase I/II trial open to patients 3 to 21 years old. For further details: <http://www.pbtc.org/public/PBTC006_HP_abstract.htm>

A Phase I/II Trial of ZD1839 (Iressa™) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II Limited to Brain Stem Tumors (PBTC007)

Children with newly diagnosed intrinsic brain stem gliomas (BSG) and incompletely resected supratentorial malignant gliomas (STMG) with residual tumor on imaging are eligible for this study. For further details: <http://www.pbtc.org/public/PBTC007_HP_abstract.htm>

Phase I Trial of Gliadel and O6–benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas (PBTC 009)

This is a phase I/II trial open to patients 3 to 21 years old. For further details: <http://www.pbtc.org/public/PBTC009_HP_abstract.htm>

A Phase II Study of Oxaliplatin in Children with Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors, [or] Atypical Teratoid Rhabdoid Tumors after Failure of Initial Therapy (PBTC 010)

This is an open-label, single-agent, phase II study of oxaliplatin in pediatric patients with recurrent or refractory embryonal central nervous system tumors. For further details: <http://www.pbtc.org/public/PBTC010_HP_abstract.htm>

For further details about clinical trials for children being performed at UCSF, visit: <http://www.cc.ucsf.edu/trials/peds_brain_toc.html>